YTHDF1 and cancer: Yue et al. (2019) found that overexpression of METTL3 is associated with a poor prognosis in GC patients and promotes epithelial-mesenchymal transition and metastasis in vivo. Another study analyzed various biological information from different human cancer databases and discovered that YTHDF1 mutations are present in approximately 7% of GC patients. Elevated YTHDF1 levels are linked with increased cancer proliferation, invasiveness, and poorer overall survival in patients (Pi et al., 2021).